(RTTNews) - Novartis AG (NVS) said Wednesday that initial results from a late-stage study showed that treatment with oral FTY720 significantly reduced relapses and disability progression in patients with multiple sclerosis compared to placebo. The company noted that comprehensive analyses of the data are ongoing, and detailed results are planned to be presented at a leading scientific congress in 2010.
Read more by clicking here
+++++++++++++++++++++++++
+++++++++++++++++++++++++
If not yet registered to receive the "Stu's Views and MS Related News", weekly Multiple Sclerosis e-newsletter, then please Click Here to register.- Thank You
+++++++++++++++++++++++++
0 comments:
Post a Comment